2003, Marketing, Regulations and Trials

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

The Pharma Data

DECEMBER 10, 2020

The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on December 11, 2020 under the ticker symbol “NBTX.” The Company’s ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol “NANO.”.

Marketing

Marketing Regulations Treatment Clinical Trials

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

The Pharma Data

JANUARY 18, 2021

The company’s common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). The company is based in Paris, France, and Cambridge, Massachusetts. Disclaimer This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts.

Regulations

Regulations Clinical Trials Production Disease

NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

The Pharma Data

OCTOBER 19, 2020

Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. About NANOBIOTIX: www.nanobiotix.com.

Clinical Trials

Clinical Trials Immune Response Trials Therapies

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

SEPTEMBER 15, 2023

BY AMANDA CONTI SEP 13, 2023 1:58 PM CDT Quick background on nonprescription drug regulation Nonprescription drugs, also known as over-the-counter (OTC) drugs, are regulated differently than traditional prescription drugs. The FDA will follow these procedures for both agency-initiated operations (e.g.,

Science

Science FDA Clinical Trials Pharmacy

NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

The Pharma Data

NOVEMBER 9, 2020

The primary endpoint of the trial is recommended phase II dose (RP2D); the secondary endpoints are objective response rate (ORR), safety and feasibility, and body-kinetics; and the exploratory endpoints are survival outcomes, duration of response, and biomarkers of response.

Immune Response

Immune Response Therapies Clinical Trials Treatment

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

DECEMBER 15, 2020

Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch. Mr. Peter Guenter, CEO of Almirall, stated, “We are delighted to partner with Athenex to market Klisyri in the U.S. Founded in 2003, Athenex, Inc.

FDA Approval

FDA Approval FDA Treatment Small Molecule

CMC Content for Global Clinical Development of Pharmaceuticals

The Premier Consulting Blog

AUGUST 21, 2024

As clinical development of an investigational product proceeds, Sponsors often conduct global clinical trials which require preparation of content to support dossiers in multiple geographies, meeting the regulatory requirements of each region. QOS – optional Module 3.2.S

Clinical Development

Clinical Development Pharmaceuticals Clinical Trials Trials

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

APRIL 8, 2024

FDA updates set the stage for broader use of harmonized standards for safety reporting Though long considered a top priority by regulators, the process to standardize and harmonize the submission of individual case safety reports (ICSRs) has been slow. Periodic Benefit-Risk Evaluation Reports ).

FDA

FDA Production Regulations Vaccine

Analysis Life Sciences Thank You Roche post-approval change submission to be first test of Accumulus Synergy’s cloud platform

Agency IQ

FEBRUARY 21, 2024

Roche post-approval change submission to be first test of Accumulus Synergy’s cloud platform Although individual regulators are increasingly adopting online, cloud-based approaches to interface with sponsors, there’s been no centralized cloud platform to support efficient submissions to multiple regulators.

Science

Science Regulations International FDA

How the Fifty States View Electronic Data as a “Product”

Drug & Device Law

JULY 31, 2023

2003), an Internal Revenue Service regulation, excluded liability for “product” refund, repair or replacement. 23, 37 (2003) (“the phrase refers to the producer of the tangible goods that are offered for sale, and not to the author of any idea, concept, or communication embodied in those goods”). 2003), review denied (Cal.

Production

Production International Trials Government

The FDA and Feasible Alternative Designs

Drug & Device Law

FEBRUARY 20, 2023

In product liability litigation generally, plaintiffs have been allowed to invent all kinds of “alternative” designs as long as some “expert” opines that the design (even if never before marketed) is “feasible.” 2003), aff’d , 810 N.Y.S.2d For physicians to prescribe such a safer drug, it must reach the market. 2d 506 (N.Y.

FDA

FDA FDA Approval Testimonials Vaccine

Logical Contradiction Doctrine: Buckman for Textualists

Drug & Device Law

JANUARY 30, 2023

Mensing , 564 U.S. Jones , 225 U.S. Davidowitz , 312 U.S. Davidowitz , 312 U.S. Davidowitz , 312 U.S. Davidowitz , 312 U.S.

FDA

FDA Regulations Production Government

Reporter’s Privilege Protects JAMA Peer-Review Documents from Discovery

Drug & Device Law

NOVEMBER 16, 2023

The plaintiffs allege that ranitidine, which had been sold under the brand name Zantac before it was removed from the market, caused them or their decedents to develop cancer. The trial court ordered JAMA to produce a privilege log and copies of the documents for in camera review. GlaxoSmithKline , 2023 IL App (1st) 221666 (2003).

Government

Government FDA Pharmaceutical Companies Regulations

Drug Discovery Digest

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

Trending Sources

NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

CMC Content for Global Clinical Development of Pharmaceuticals

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Analysis Life Sciences Thank You Roche post-approval change submission to be first test of Accumulus Synergy’s cloud platform

How the Fifty States View Electronic Data as a “Product”

The FDA and Feasible Alternative Designs

Logical Contradiction Doctrine: Buckman for Textualists

Reporter’s Privilege Protects JAMA Peer-Review Documents from Discovery

Stay Connected